stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Operating cash flow
Halozyme Therapeutics, Inc.'s operating cash flow for fiscal 2025 was $651.6M, up 36.0% from $479.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $898.3M. Over the past ten years it has ranged from −$85.4M (fiscal 2019) to $651.6M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Halozyme Therapeutics, Inc. ranks 9th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $651.6M | 36.01% |
| FY2024 | $479.1M | 23.29% |
| FY2023 | $388.6M | 61.83% |
| FY2022 | $240.1M | (19.81%) |
| FY2021 | $299.4M | 439.98% |
| FY2020 | $55.5M | — |
| FY2019 | −$85.4M | — |
| FY2018 | −$49.5M | — |
| FY2017 | $134.1M | — |
| FY2016 | −$50.4M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $258.3M | 7.21% |
| Jun 2026 | $240.9M | 33.77% |
| Mar 2026 | $180.1M | (17.78%) |
| Dec 2025 | $219.0M | 22.64% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.7B |
| EXEL Exelixis, Inc. compare | $1.2B |
| HALO Halozyme Therapeutics, Inc. | $898.3M |
| BMRN BioMarin Pharmaceutical Inc. compare | $676.6M |
| ASND Ascendis Pharma A/S compare | $404.1M |
| TECH Bio-Techne Corp compare | $292.1M |
| KYMR Kymera Therapeutics, Inc. compare | −$287.6M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.0M |
| SMMT Summit Therapeutics PLC compare | −$458.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement